Refine
Year of publication
Language
- English (25)
Has Fulltext
- yes (25)
Is part of the Bibliography
- no (25)
Keywords
- EWSR1 (2)
- Gene fusion (2)
- 16p11.2 (1)
- ADHD (1)
- Acute HIV infection (1)
- Acute coronary syndrome (1)
- Alleles (1)
- Angioplasty (1)
- Atomic and Molecular Physics (1)
- Atrial fibrillation (1)
- Autism (1)
- Ayurveda (1)
- Biomarkers (1)
- Bipolar disorder (1)
- Brain tumor (1)
- CD4 binding site (1)
- COVID-19 (1)
- CRISPR/Cas9 (1)
- Cardiac troponin (1)
- Cardiovascular biology (1)
- Consortia (1)
- Depression (1)
- Diagnostic markers (1)
- Diagnostic medicine (1)
- EP300 (1)
- Etiology (1)
- FOXO1 (1)
- Fibroblast growth factor (1)
- Genome-wide association studies (1)
- HIV (1)
- HIV-1 (1)
- HIV-1 escape restriction (1)
- Heart failure (1)
- Hemodynamics (1)
- Kynurenine (1)
- MN1 (1)
- Molecular genetics (1)
- Myocardial infarction (1)
- Natriuretic peptide (1)
- Neuroepithelial (1)
- Neuroepithelial tumor (1)
- Neurooncology (1)
- Outcome (1)
- PARK2 (1)
- PATZ1 (1)
- PCR (1)
- PLAGL1 (1)
- Pediatric (1)
- Prognostic markers (1)
- Pulmonary embolism (1)
- Pulmonary hypertension (1)
- Quinolinate phosphoribosyltransferase (1)
- Quinolinic acid (1)
- Rapid diagnostic test (1)
- Risk prediction (1)
- SARS-CoV-2 (1)
- Schizophrenia (1)
- Seroconverter (1)
- Sholl analysis (1)
- Supratentorial (1)
- Traditional Indian Medicine (1)
- Troponin (1)
- biomarker (1)
- broadly neutralizing antibodies (1)
- chronic kidney disease (1)
- circadian variation (1)
- clinical trials (1)
- cohort study (1)
- complementary medicine (1)
- continuous glucose monitoring (1)
- cryogenic electron microscopy (1)
- decision aids (1)
- deep mutational scanning (1)
- diabetes (1)
- diagnostic test (1)
- disease modelling (1)
- escape mutations (1)
- hiPSC (1)
- humanized mice (1)
- immunotherapy (1)
- integrative medicine (1)
- irritable bowel syndrome (1)
- many-electron correlation (1)
- miRNAs (1)
- mitochondria (1)
- mutational antigenic profiling (1)
- non-ST-segment elevation acute coronary syndrome (1)
- nutrition - clinical (1)
- one-photon double ionization (1)
- pregnancy (1)
- rat (1)
- two-electron systems (1)
Institute
Multiplex families with a high prevalence of a psychiatric disorder are often examined to identify rare genetic variants with large effect sizes. In the present study, we analysed whether the risk for bipolar disorder (BD) in BD multiplex families is influenced by common genetic variants. Furthermore, we investigated whether this risk is conferred mainly by BD-specific risk variants or by variants also associated with the susceptibility to schizophrenia or major depression. In total, 395 individuals from 33 Andalusian BD multiplex families (166 BD, 78 major depressive disorder, 151 unaffected) as well as 438 subjects from an independent, BD case/control cohort (161 unrelated BD, 277 unrelated controls) were analysed. Polygenic risk scores (PRS) for BD, schizophrenia (SCZ), and major depression were calculated and compared between the cohorts. Both the familial BD cases and unaffected family members had higher PRS for all three psychiatric disorders than the independent controls, with BD and SCZ being significant after correction for multiple testing, suggesting a high baseline risk for several psychiatric disorders in the families. Moreover, familial BD cases showed significantly higher BD PRS than unaffected family members and unrelated BD cases. A plausible hypothesis is that, in multiplex families with a general increase in risk for psychiatric disease, BD development is attributable to a high burden of common variants that confer a specific risk for BD. The present analyses demonstrated that common genetic risk variants for psychiatric disorders are likely to contribute to the high incidence of affective psychiatric disorders in the multiplex families. However, the PRS explained only part of the observed phenotypic variance, and rare variants might have also contributed to disease development.
Broadly neutralizing antibodies (bNAbs) represent a promising approach to prevent and treat HIV-1 infection. However, viral escape through mutation of the HIV-1 envelope glycoprotein (Env) limits clinical applications. Here we describe 1-18, a new VH1-46-encoded CD4 binding site (CD4bs) bNAb with outstanding breadth (97%) and potency (GeoMean IC50 = 0.048 μg/mL). Notably, 1-18 is not susceptible to typical CD4bs escape mutations and effectively overcomes HIV-1 resistance to other CD4bs bNAbs. Moreover, mutational antigenic profiling uncovered restricted pathways of HIV-1 escape. Of most promise for therapeutic use, even 1-18 alone fully suppressed viremia in HIV-1-infected humanized mice without selecting for resistant viral variants. A 2.5-Å cryo-EM structure of a 1-18-BG505SOSIP.664 Env complex revealed that these characteristics are likely facilitated by a heavy-chain insertion and increased inter-protomer contacts. The ability of 1-18 to effectively restrict HIV-1 escape pathways provides a new option to successfully prevent and treat HIV-1 infection.
A central motivation for the development of x-ray free-electron lasers has been the prospect of time-resolved single-molecule imaging with atomic resolution. Here, we show that x-ray photoelectron diffraction—where a photoelectron emitted after x-ray absorption illuminates the molecular structure from within—can be used to image the increase of the internuclear distance during the x-ray-induced fragmentation of an O2 molecule. By measuring the molecular-frame photoelectron emission patterns for a two-photon sequential K-shell ionization in coincidence with the fragment ions, and by sorting the data as a function of the measured kinetic energy release, we can resolve the elongation of the molecular bond by approximately 1.2 a.u. within the duration of the x-ray pulse. The experiment paves the road toward time-resolved pump-probe photoelectron diffraction imaging at high-repetition-rate x-ray free-electron lasers.
Ependymomas encompass a heterogeneous group of central nervous system (CNS) neoplasms that occur along the entire neuroaxis. In recent years, extensive (epi-)genomic profiling efforts have identified several molecular groups of ependymoma that are characterized by distinct molecular alterations and/or patterns. Based on unsupervised visualization of a large cohort of genome-wide DNA methylation data, we identified a highly distinct group of pediatric-type tumors (n = 40) forming a cluster separate from all established CNS tumor types, of which a high proportion were histopathologically diagnosed as ependymoma. RNA sequencing revealed recurrent fusions involving the pleomorphic adenoma gene-like 1 (PLAGL1) gene in 19 of 20 of the samples analyzed, with the most common fusion being EWSR1:PLAGL1 (n = 13). Five tumors showed a PLAGL1:FOXO1 fusion and one a PLAGL1:EP300 fusion. High transcript levels of PLAGL1 were noted in these tumors, with concurrent overexpression of the imprinted genes H19 and IGF2, which are regulated by PLAGL1. Histopathological review of cases with sufficient material (n = 16) demonstrated a broad morphological spectrum of tumors with predominant ependymoma-like features. Immunohistochemically, tumors were GFAP positive and OLIG2- and SOX10 negative. In 3/16 of the cases, a dot-like positivity for EMA was detected. All tumors in our series were located in the supratentorial compartment. Median age of the patients at the time of diagnosis was 6.2 years. Median progression-free survival was 35 months (for 11 patients with data available). In summary, our findings suggest the existence of a novel group of supratentorial neuroepithelial tumors that are characterized by recurrent PLAGL1 fusions and enriched for pediatric patients.
Background: Patients with chronic kidney disease (CKD) are at high risk of myocardial infarction. Cardiac troponins are the biomarkers of choice for the diagnosis of acute myocardial infarction (AMI) without ST‐segment elevation (NSTE). In patients with CKD, troponin levels are often chronically elevated, which reduces their diagnostic utility when NSTE‐AMI is suspected. The aim of this study was to derive a diagnostic algorithm for serial troponin measurements in patients with CKD and suspected NSTE‐AMI.
Methods and Results: Two cohorts, 1494 patients from a prospective cohort study with high‐sensitivity troponin I (hs‐cTnI) measurements and 7059 cases from a clinical registry with high‐sensitivity troponin T (hs‐cTnT ) measurements, were analyzed. The prospective cohort comprised 280 CKD patients (estimated glomerular filtration rate <60 mL/min/1.73 m2). The registry data set contained 1581 CKD patients. In both cohorts, CKD patients were more likely to have adjudicated NSTE‐AMI than non‐CKD patients. The specificities of hs‐cTnI and hs‐cTnT to detect NSTE‐AMI were reduced with CKD (0.82 versus 0.91 for hs‐cTnI and 0.26 versus 0.73 for hs‐cTnT) but could be restored by applying optimized cutoffs to either the first or a second measurement after 3 hours. The best diagnostic performance was achieved with an algorithm that incorporates serial measurements and rules in or out AMI in 69% (hs‐cTnI) and 55% (hs‐cTnT) of CKD patients.
Conclusions: The diagnostic performance of high‐sensitivity cardiac troponins in patients with CKD with suspected NSTE‐AMI is improved by use of an algorithm based on admission troponin and dynamic changes in troponin concentration.